Patents: Patent Strategies for Biotechnology Enterprises - A patent is an asset that can improve competitive advantage and boost profits, yet many biotech firms miss opportunities to take full strateg

ADVERTISEMENT

Patents: Patent Strategies for Biotechnology Enterprises
A patent is an asset that can improve competitive advantage and boost profits, yet many biotech firms miss opportunities to take full strategic advantage of their patents.


BioPharm International
Volume 20, Issue 8

REFERENCES

1. Organisation for Economic Co-operation and Development (OECD). OECD policy brief: Intellectual property and competition policy in the biotechnology industry. Paris: OECD Headquarters; 2005 June.

2. Isacson JP. Maximizing profits through intelligent planning and implementation. Nat Biotechnol 2000 May;18(5):565-6.

3. Amgen, Inc. vs Hoechst Marion Roussel, Inc., 3F supp 2d 104 (D Mass 1998). Amgen, Inc. vs Elanex Parm., Inc., No C93-1483D, 1996 WL 84590 (WD Wash Feb 6, 1996). Amgen, Inc. vs Genetics Inst., Inc., 877 F supp 45 (D Mass 1995) affd, 98 F3d 1328 (Fed Cir 1996).

4. Brown RJ, Levitt KE. An effective patent strategy: What it is, and how to implement it. Hennepin Lawyer 2003 Mar;72(3):16-23.

5. Lanjouw J, Schankerman M. Stylized facts of patent litigation: Value, scope and ownership. National Bureau of Economic Research Working Paper No. W6297. Cambridge (MA): National Bureau of Economic Research; 1997.

6. Lanjouw J, Schankerman M. Characteristics of patent litigation: A window on competition. Rand J of Econ 2001 Spr;32(1):129-51.

7. Lanjouw J, Schankerman M. An empirical analysis of the enforcement of patent rights in the United States. In: Cohen WM, Merrill S, editors. Patents in the knowledge-based economy. Washington: National Academy Press; 2003.

8. Organisation for Economic Co-operation and Development (OECD). Patents, innovation and economic performance. Proceedings of the OECD Conference on Intellectual Property Rights, Innovation and Economic Performance; 2003 Aug 28-29; Paris, France. Paris: OECD Headquarters; 2003.

9. Miele AL. Patent strategy: The manager's guide to profiting from patent portfolios. Hoboken (NJ): John Wiley & Sons; 2001.

10. McGarrigle P. Qtd in: Huebner SR. Orientation in the patent jungle. European Private Equity and Venture Capital Association (EVCA) Conference Journal [online] 2005 Oct 19-21[cited 2007 Jul 1]:10. Available from: URL: http:// http://www.kennet.com/images/Conference_Journal_2005.pdf

11. Grindley PC, Teece DJ. Managing intellectual capital: Licensing and cross-licensing in semiconductors and electronics. California Mgt Rev 1997;29:8-41.

12. Shapiro C. Antitrust limits to patent settlements. Rand J of Econ 2003 Su;34(2): 391-411.

13. Hyseq vs Affymetrix, No 97-20188 (ND Cal Mar 3, 1997). See Rouse R, Hardiman G. Microarray technology-An intellectual property perspective, 4 Pharmacogenomics 2003;4(5);623-32.

14. Levy IJ, Fernands AM. Building a strong case for the defence. Intellectual Asset Mgt 2006 Feb; Special Report, IP Value in the Life Sciences Industries:17-20.

15. Yeh JJ, Fernandez D, Hansen N. Patent prosecution strategies for stem cell-related applications. J of the Patent and Trademark Office Soc [online] 2006 Jan [cited 2007 July 1];88(1). Available from: http:// http://www.jptos.org/pages.php?menuid=22&pagenum=2


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here